Trials / Not Yet Recruiting
Not Yet RecruitingNCT07528053
A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants
A Phase 1, Open-Label, Single Dose Bridging Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805-2 in Healthy Participants
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1 Clinical Study Of BW-20805-2-1001 in Healthy Participants
Detailed description
A Phase 1, Open-Label, Single Dose Bridging Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805-2 in Healthy Participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BW-20805 | Cohort 1 will receive SC administrations of BW-20805 on Day1. |
| DRUG | BW-20805 | Group 2 will receive SC administrations of BW-20805 on Day1 |
| DRUG | BW-20805-2 | Group 3 will receive SC administrations of BW-20805-2 on Day1. |
Timeline
- Start date
- 2026-04-28
- Primary completion
- 2026-06-30
- Completion
- 2027-11-05
- First posted
- 2026-04-14
- Last updated
- 2026-04-14
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT07528053. Inclusion in this directory is not an endorsement.